Effectiveness of ECP Therapy in Stable Angina Pectoris Patients
Launched by UNIVERSITAS PADJADJARAN · Apr 29, 2021
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a treatment called External Counterpulsation (ECP) for patients with stable angina pectoris, which is a type of chest pain caused by reduced blood flow to the heart. ECP is a non-invasive therapy that uses pressure cuffs to help improve blood flow and relieve symptoms, especially for those waiting for heart surgery like coronary artery bypass grafting (CABG). The goal of the study is to see if adding ECP to standard medical therapy can provide better results for patients who are experiencing ongoing chest pain.
To be eligible for this trial, participants need to be at least 18 years old and diagnosed with stable angina pectoris, with specific issues in their heart's blood vessels. They should be on a waiting list for CABG or have chosen medical therapy instead of surgery. Participants will undergo tests to monitor their heart health and symptoms, and they will need to be willing to follow the study's procedures. It’s essential that participants live in the Bandung City area and are available to take part in the research during working hours if needed.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>= 18 years old
- • Diagnosed with stable angina pectoris
- • Anatomic vessel disease (VD) lesion with 2VD/3VD
- • Indicated for CABG and in waiting list of CABG procedure; or refuse for CABG and choose medical therapy only; or patients who are decided by the responsible doctor for medical treatment alone because of the high risks of CABG surgery.
- • Not planned to urgent CABG
- • Minimum optimal medical therapy within 2 weeks
- • Able and willing to sign informed consent and comply with study procedures
- • The patient lives in Bandung City and its neighborhood
- • Retired patient; or not actively working during working hours; or willing to take the time to participate in research.
- Exclusion Criteria:
- • Congestive Heart Failure
- • Chronic heart failure with Functional Class NYHA III - IV
- • LVEF \<35%
- • Unprotected left main stenosis \>50%
- • Blood pressure \>180/110mmHg
- • Acute coronary syndrome
- • Acute Heart Failure
- • Severe aorta regurgitation
- • Malignant arrhythmia
- • Atrial fibrillation
- • Premature ventricular complex
- • Peripheral occlusive artery disease
- • Phlebitis
- • Deep vein thrombosis
- • Hemorrhagic diathesis
- • Severe chronic kidney disease
- • Aortic aneurysm
- • Abdominal aneurysm
- • Osteoarthritis
- • Low back pain
- • Pregnancy
- • Registered as other clinical study participant
About Universitas Padjadjaran
Universitas Padjadjaran, a prestigious academic institution in Indonesia, is dedicated to advancing medical research and clinical trials that contribute to the improvement of healthcare outcomes. With a strong emphasis on interdisciplinary collaboration and innovation, the university harnesses its extensive resources and expertise to conduct rigorous studies aimed at addressing pressing health challenges. Through its commitment to ethical research practices and community engagement, Universitas Padjadjaran plays a pivotal role in fostering evidence-based medicine and enhancing the quality of life for diverse populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bandung, West Java, Indonesia
Patients applied
Trial Officials
Mohammad R Akbar, MD, FIHA.
Principal Investigator
Universitas Padjadjaran
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials